|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
MAPK-activated protein kinase II (MK2), downstream kinase of p38 mitogen activated protein kinase (MAPK) p38 MAPK, was unveiled as a promising option for the treatment of AD.
|
31849936 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier analysis of data in patients with breast cancer suggested that, higher expression of ERK1 was associated with better prognosis, whereas, higher expression of ERK2 predicted poorer prognosis.
|
31848326 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier analysis of data in patients with breast cancer suggested that, higher expression of ERK1 was associated with better prognosis, whereas, higher expression of ERK2 predicted poorer prognosis.
|
31848326 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both lesions were squamous cell carcinoma and positive for p40.
|
31845086 |
2019 |
|
Fibrosis, Liver
|
0.070 |
Biomarker
|
disease |
BEFREE |
Macrophage MerTK promotes an ERK-TGFβ1 pathway that activates HSCs and induces liver fibrosis.
|
31839486 |
2020 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical HCC samples exhibited a positive correlation between circASAP1 expression and levels of CSF-1, MAPK1, and CD68+ tumor-associated-macrophages, all of which were predictive of patient outcomes.Conclusion: We identified circASAP1 as a key regulator of HCC metastasis that acts on miR-326/miR-532-5p-MAPK1/CSF-1 signaling and serves as a prognostic predictor in patients with HCC.
|
31838741 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, UBE2Z knockdown could effectively reduce the expression of p-ERK, p-p38, p-JNK, p-Stat3 and p-JAK2, suggesting that UBE2Z might promote HCC progression by targeting ERK and stat3 signaling pathway.
|
31831168 |
2020 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
After suppressing the p38 pathway, the chondrogenesis can be inhibited, which can be used to guide the treatment of osteoarthritis.
|
31831024 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of alpha-crystallin B in T24 and J82 BC cell lines resulted in significant inhibition of tumour cell migration and invasion, which was associated with a decrease in PI3K, AKT and ERK activation.
|
31829429 |
2020 |
|
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab and briakinumab are monoclonal antibodies that target the standard p40 subunit of cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease (CD).
|
31828765 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A detailed mechanistic understanding of how p38 MAPK family members function is urgently warranted for cancer targeted therapy.
|
31828036 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A detailed mechanistic understanding of how p38 MAPK family members function is urgently warranted for cancer targeted therapy.
|
31828036 |
2019 |
|
Adenocarcinoma of pancreas
|
0.040 |
Biomarker
|
disease |
BEFREE |
p38α Mitogen-Activated Protein Kinase Is a Druggable Target in Pancreatic Adenocarcinoma.
|
31828036 |
2019 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Mechanistically, silencing of IL13RA2 promotes partial epithelial-mesenchymal transition via increasing ERK phosphorylation in HCC.
|
31823484 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, the combination of an MEK or ERK inhibitor with a first-generation (eg, erlotinib) or second-generation (eg, afatinib) EGFR-TKI also very effectively inhibited the growth of osimertinib-resistant cells in vitro and of tumors in vivo, although these cell lines were cross-resistant to first-generation or second-generation EGFR-TKIs.
|
31821539 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib.
|
31821539 |
2020 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neuroprotective Effect of S-trans, Trans-farnesylthiosalicylic Acid via Inhibition of RAS/ERK Pathway for the Treatment of Alzheimer's Disease.
|
31819374 |
2019 |
|
Pancreatic carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Briefly, the ceRNA regulatory network of circ-ADAM9/miR-217/PRSS3 plays a pivotal role in PC progression by the regulation of ERK/VEGF signalling pathway.
|
31810373 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Briefly, the ceRNA regulatory network of circ-ADAM9/miR-217/PRSS3 plays a pivotal role in PC progression by the regulation of ERK/VEGF signalling pathway.
|
31810373 |
2019 |
|
Jaundice, Obstructive
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
All these data demonstrated that p38 MAPK-pHsp27 mediates vascular hyporesponsiveness in rats with obstructive jaundice by modulating the expression level of pHsp27 and F-actin, and that inhibition of p38 MAPK signaling could remodel the vascular activity.
|
31810142 |
2020 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sputum protein lysates were analysed for p38 activation in a validation study (n = 24 asthma, n = 8 healthy) by western blotting.
|
31808595 |
2019 |
|
Inflammatory pain
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Our results indicate that MCT 1 very likely play a critical role in regulating chronic inflammatory pain and may influence the regulation of synaptic plasticity via ERK in the spinal dorsal horn of rats.
|
31807055 |
2019 |
|
Solid Neoplasm
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
We interrogated the well-described mechanism of MEK/ERK pathway inhibitor addiction in solid tumors and found it does not apply to ALCL.
|
31804622 |
2020 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We interrogated the well-described mechanism of MEK/ERK pathway inhibitor addiction in solid tumors and found it does not apply to ALCL.
|
31804622 |
2020 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We interrogated the well-described mechanism of MEK/ERK pathway inhibitor addiction in solid tumors and found it does not apply to ALCL.
|
31804622 |
2020 |